VRDN-002, a Next-Generation Half-life Extended Antagonist Antibody to IGF-1 Receptor for Thyroid Eye Disease (TED): Safety and Pharmacokinetic/Pharmacodynamic (PK/PD) Results in Healthy Volunteers
You are now leaving the Viridian Therapeutics website.
You are about to leave the Viridian Therapeutics website for another external website. Viridian Therapeutics has no responsibility for the content of such other sites and is not liable for any damages or injury arising from that content. Any links to other sites are provided merely as a convenience to the users of this website.